Categories Earnings, Finance

Royal Bank of Scotland (NYSE: RBS): Q4 2019 Earnings Snapshot

— The Royal Bank of Scotland Group Plc (NYSE: RBS) reported its fourth-quarter 2019 earnings of GBP0.116 per share, up from GBP0.023 per share in the previous year quarter.

— Operating profit before tax soared to GBP1.55 billion from GBP572 million last year.

Earnings Update by AlphaStreet

— Across the retail and commercial businesses, income declined by 4% excluding notable items, principally reflecting margin pressure in a challenging market.

— The bank net interest margin declined by 4 basis points from last quarter, primarily reflecting competitive pressures in the mortgage business as front book margins remain lower than the back book.

— The company said it plans to rename its parent company to NatWest Group Plc later this year.

— The company continues to expect challenges on income in the current environment and ongoing market uncertainty. The regulatory changes will adversely impact income in personal business by around GBP200 million.

— The company plans ongoing operating costs take out by lowering operating expenses excluding strategic costs, litigation and conduct costs and operating lease depreciation costs by GBP250 million in 2020 compared with 2019.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

DIS Earnings: All you need to know about Walt Disney’s Q4 2025 earnings results

The Walt Disney Company (NYSE: DIS) reported its fourth quarter 2025 earnings results today. Revenues of $22.5 billion were comparable to the year-ago quarter. Net income attributable to The Walt

Cisco (CSCO) reports higher Q1 revenue and earnings; results beat estimates

Network gear maker Cisco Systems Inc. (NASDAQ: CSCO) on Wednesday announced financial results for the first quarter of fiscal 2026, reporting higher revenue and profit. Earnings, on an adjusted basis,

Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO

CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on hematologic malignancies and solid tumors. In an email conversation with

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top